Cardiol Therapeutics (TSX:CRDL) Net Issuance of Preferred Stock : C$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Cardiol Therapeutics Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Cardiol Therapeutics's net issuance of preferred for the three months ended in Dec. 2023 was C$0.00 Mil. The number is 0, which means that Cardiol Therapeutics has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Cardiol Therapeutics's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.00 Mil.

Cardiol Therapeutics Net Issuance of Preferred Stock Historical Data

The historical data trend for Cardiol Therapeutics's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiol Therapeutics Net Issuance of Preferred Stock Chart

Cardiol Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Cardiol Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Cardiol Therapeutics Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

Cardiol Therapeutics Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Cardiol Therapeutics's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiol Therapeutics (TSX:CRDL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cardiol Therapeutics Inc (TSX:CRDL) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

CRDL:USA CT9:Germany

Address

2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5

Website

https://www.cardiolrx.com

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Cardiol Therapeutics (TSX:CRDL) Headlines

From GuruFocus

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews • 06-13-2022

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews • 07-03-2022

Heart Failure and CBD -- CFN Media

By Marketwired Marketwired • 02-20-2019

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By PurpleRose PurpleRose • 07-13-2022

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews • 05-24-2022

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews • 06-03-2022

Cardiol Therapeutics to Webcast Live at VirtualInvestorConferences.com on June 4ᵗʰ

By PRNewswire PRNewswire • 06-03-2019

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews • 06-23-2022